Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Terumo cardiovascular systems (terumo cvs) has determined that changes made when upgrading cdi system 500 software from version 1.65 to version 1.69 were not expected or fully understood by users and that the following user instructions need to be clarified: in-vivo calibration: measured values prior to initial in-vivo calibration may not be used for patient management. at the beginning of a case you must complete calibration of all measurable blood parameters by comparing them to a laboratory measurement done on a blood sample. the values are dimmed on the cdi system 500 screen to indicate that the values are not accurate until an initial in-vivo calibration is performed. operating ranges: if a lab measured value is outside the operating range for a parameter you may not be able to adjust the cdi system 500 measured value to the lab measured value. accuracy has not been established for displayed values outside the operating range. therefore displayed values outside the operating range should not be used for patient management. while this condition exists continue patient management with another source (i.E. laboratory or point-of-care blood gas analyzer). see cdi system 500 operating ranges: reference table for system accuracy limits. temperature: the temperature measured by the shunt sensor is local to the sensor and does not reflect the actual patient arterial temperature. do not use this measurement for patient management.